Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Consolidated Statements of Operations
Net Revenues	$ 316,385	$ 216,136	$ 208,475
Operating Expenses
Cost of sales (excluding depreciation and amortization)	138,785	100,610	87,157
Research and development	22,318	11,369	16,001
Selling, general, and administrative	124,044	84,294	64,986
Depreciation and amortization	56,972	47,252	44,638
Contingent consideration fair value adjustment	3,758	500
Legal settlement expense		8,750
Purified Cortrophin Gel pre-launch charges		780	11,263
Restructuring activities	5,679
Intangible asset impairment charge	112	2,374	446
Total Operating Expenses	351,668	255,929	224,491
Operating Loss	(35,283)	(39,793)	(16,016)
Other Expense, net
Interest expense, net	(28,052)	(11,922)	(9,452)
Other income/(expense), net	670	(4,343)	(494)
Loss Before Benefit for Income Taxes	(62,665)	(56,058)	(25,962)
Benefit for income taxes	14,769	13,455	3,414
Net Loss	(47,896)	(42,603)	(22,548)
Dividends on Series A Convertible Preferred Stock	(1,625)	(190)
Net Loss Available to Common Shareholders	$ (49,521)	$ (42,793)	$ (22,548)
Basic and Diluted Loss Per Share:
Basic Loss Per Share	$ (3.05)	$ (3.40)	$ (1.88)
Diluted Loss Per Share	$ (3.05)	$ (3.40)	$ (1.88)
Basic Weighted-Average Shares Outstanding	16,260	12,596	11,964
Diluted Weighted-Average Shares Outstanding	16,260	12,596	11,964